Introduction
============

Hepatocellular carcinoma (HCC) is one of the most lethal malignancies ranking as the fifth most common cancer worldwide ([@b1-or-38-02-0886]). The incidence of advanced HCC cases who underwent multiple metastasis and dismal prognosis is increasing and usually the lack of effective treatment options will lead to serious social burdens ([@b2-or-38-02-0886]). Currently, radical or partial hepatectomy represents the standard of care for patients with early diagnosis. However, distant metastases and postoperative relapse remain tremendous challenges. Therefore, identification of potential new therapeutic targets and prognostic biomarkers would be of great benefit to HCC patients.

Recent advance suggests that inflammation plays a critical role in carcinogenesis. As pivotal mediators in the inflammatory response, macrophages could generally be polarized into two principal subtypes: classically activated macrophages (M1) and alternatively activated macrophages (M2) ([@b3-or-38-02-0886]). However, the two classes of macrophages play a diverse role in exhibiting pro- and anti-inflammatory activities, respectively. Tumor-associated macrophages (TAMs) are recruited to tumors by various cytokines and growth factors ([@b4-or-38-02-0886]). They are widely documented as a fundamental cellular component within the tumor immune microenvironment, even having distinct phenotypes of TAMs at different stages of the tumor ([@b5-or-38-02-0886]). TAMs substantially affect the fate of cancer cells and the clinical outcome by interacting in a complicated manner with neoplastic cells ([@b6-or-38-02-0886],[@b7-or-38-02-0886]). Generally, TAMs are of M2-like phenotype and have a protumor role. This is supported by the evidence that these macrophages can promote tumor progression and metastasis by orchestrating tumor cell motility, invasion, angiogenesis and antitumor immunity ([@b8-or-38-02-0886],[@b9-or-38-02-0886]). In majority of solid tumors, TAMs were often associated with decreased patient survival ([@b10-or-38-02-0886]--[@b12-or-38-02-0886]). Nonetheless, conflicting results have been observed by several investigators in some types of cancers, for example, non-small cell lung cancer and papillary renal cell carcinoma ([@b13-or-38-02-0886],[@b14-or-38-02-0886]).

CD68 is commonly considered to be a pan-macrophage marker ([@b15-or-38-02-0886],[@b16-or-38-02-0886]). However, CD68 cannot distinguish M1 or M2 subtype from all the pan-macrophages ([@b15-or-38-02-0886]). In addition to its existence in resident macrophages of multiple tissues, CD68 is also expressed in tumor-infiltrating macrophages. CD206 is known to be expressed on the surface of most classes of macrophages and dendritic cell subpopulations, and is routinely used to identify the M2 phenotype ([@b17-or-38-02-0886]). CD206 is involved in antigen presentation, endocytosis and phagocytosis, signal transduction, innate host defense and the adaptive immune response ([@b18-or-38-02-0886]). To date, both CD68 and CD206 have been the subjects of extensive structural and functional investigation in human diseases, especially in tumors. The associations of CD68-positive or CD206-positive macrophages with poor prognosis have been extensively documented in various types of malignancies, such as oral squamous cell carcinoma, breast cancer and HCC ([@b19-or-38-02-0886]--[@b24-or-38-02-0886]). However, the clinical relevance of macrophages infiltration to distinct histologic locations to HCC prognosis remained unclear. A better understanding of the roles of CD68 and CD206 macrophages in HCC may provide valuable information for prevention and treatment of HCC. Herein, we initiated a comparative follow-up study to explore their distribution and expression, as well as prognostic value in primary HCC.

Materials and methods
=====================

### Patients and specimens

A total of 268 anonymized patients with primary HCC were collected and pathologically confirmed by Pathology Department of the First Affiliated Hospital of Anhui Medical University were enrolled in the present study. All the patients aged \>18 years underwent surgical curative resection with follow-up from October 2011 to December 2016. Concurrence of other malignant diseases, autoimmune disease, syphilis and human immunodeficiency virus were excluded from the study. None of the cases received chemotherapy and/or radiotherapy previous to surgery. Total of 266 primary tumor tissues were grouped into case subjects and 243 tumor adjacent tissues were evaluated as the control group. Paired, formalin-fixed and paraffin-embedded (FFPE) primary tumor tissues and tumor adjacent tissues specimens were obtained from the whole patient population. This study was approved by the Human Research Ethics Committee of Anhui Medical University. Informed consents were obtained from all the participating patients.

In the present study, the hematoxylin and eosin slides were independently examined, and the histological diagnoses were re-evaluated systematically by two experienced pathologists who were blinded to the clinical outcome of the samples based on WHO classifications of HCC. Clinical stages of tumor progression were determined according to the tumor-node-metastasis (TNM) classification system of the International Union against Cancer/American Joint Committee on Cancer (IUAC/AJCC) (Edition 7). The following clinical data were obtained in a well-designed questionnaire, including TNM stage, demographics (sex and age), family history, alcohol consumption, laboratory data including alpha fetoprotein (AFP), serum albumin and total bilirubin (TBIL).

### Reagents

The following primary antibodies were used: mouse anti-CD68 antibody (KP1) (cat. no. ab845), mouse anti-CD206 antibody (cat. no. ab117644) and they were obtained from Abcam (Cambridge, MA, USA). Anti-CD68 antibody was prediluted. The anti-CD206 antibody was applied at a dilution of 1:200. Both immunohistochemical MaxVision kit and diaminobenzidine (DAB) chromogenic reagent kit were purchased from Fuzhou Maixin Biotech, Co., Ltd. (Fuzhou, China).

### Immunohistochemistry

We detected the expression of CD206 and CD68 in two different areas with IHC staining and further calculated their distribution densities. FFPE tissue sections (4 µm-thick) were processed for IHC staining with mouse anti-human CD68 antibody and mouse anti-human CD206 antibody as described. IHC assay was performed with MaxVision IHC kit and DAB chromogenic reagent kit. Briefly, the protocol was as described below. First, the tissue sections were deparaffinized and hydrated, immersed in ethylene diamine tetraacetic acid buffer (PH 8.0) and heated for 15 min in a microwave oven for antigen retrieval. Next, the primary antibody against CD68 or CD206 was added to the specimen sections at 4°C and incubated overnight, which were then developed using the immunohistochemical MaxVision kit. The primary antibody was removed, and the secondary antibody was incubated with the samples (1:1,000) at 37°C for 30 min. The kit solution was incubated with tissue samples at room temperature for 20 min, and thereafter, DAB chromogenic reagent was added. Finally, hematoxylin staining was carried out. The primary antibody was replaced with phosphate buffered saline, which was used as the negative control. IHC staining of positive samples was repeated twice.

### Counting

The tan or brown granules in the cytoplasm of cancer or adjacent cancer macrophages observed in the IHC assay were considered positive staining. Quantitative analysis of CD68 and CD206 in the stained sections was independently performed by two pathologists blinded to the clinical data. The mean score of five high-power fields (HPF) (×400) was counted for each slide by an optical microscope of Leica (DM2500; Leica Microsystems, Wetzlar, Germany).

### Follow up study

Follow-up evaluations were performed every 3 months for the first year and annually thereafter for locally advanced tumor stages. Among all the 268 patients, 199 patients who completed the follow-up were further enrolled in survival analysis (69 cases were dropped). The scores of CD68-positive and CD206-positive were compared with demographical, clinical and histopathological characteristics. All these variables were tested as predictors of patients OS and DFS. OS was defined as the interval between the dates of surgery and death or the last follow-up. DFS was defined as the interval between the dates of surgery and the first recurrence or the latest date of follow-up.

### Statistical analysis

Statistical Package for Social Sciences version 16.0 (SPSS 16.0; SPSS Inc., Chicago, IL, USA), MedCalc version 11.4.2.0 (MedCalc Software, Mariakerke, Belgium) and Graphpad Prism version 5.0 (Graphpad Software, Inc., La Jolla, CA, USA) were used in the present study. Quantitative variables following a normal distribution were presented as mean ± standard deviation (SD), and the difference between/among groups were tested using t-test or one-way ANOVA. Quantitative variables with a skewed distribution were presented as medians with interquartile ranges (IQRs), and the differences between/among groups were tested using Mann-Whitney U test and Kruskal-Wallis test. Correlations of CD68/CD206-positive macrophages between the intratumor and the tumor adjacent tissue or between the two types of infiltrated macrophages were tested using the non-parametric Spearmans rank analysis. Then, the receiver operating characteristics (ROC) curve analysis was plotted to calculate the diagnostic accuracy of CD68 and CD206. The optimum cut-off value for diagnosis was determined by maximizing the sum of sensitivity and specificity. In addition, Kaplan-Meier survival curves and log-rank test were used to analyze the correlations between the CD68-positive and the CD206-positive macrophage numbers and survival of postsurgical HCC patients. Finally, Cox proportional hazards regression was employed for univariate and multivariate analysis of OS and DFS. Differences were considered statistically significant at two-sided P\<0.05.

Results
=======

### The clinicopathological characteristics of HCC patients

This study comprised 268 patients with HCC and their clinicopathological parameters are given in [Table I](#tI-or-38-02-0886){ref-type="table"}. The majority of cases were male (229, 85.4%) and nearly 50% of cases were aged under 54 years. Among the cases, near 80% (209, 78%) had positive HBV and nearly half (112, 41.8%) HCC cases presented liver cirrhosis. Of these patients, 264 (98.51%) were considered early stage HCC: Child-Pugh-A (n=238, 88.8%), Child-Pugh-B (n=26, 9.7%) and Child-Pugh-C (n=4, 1.5%).

### Distribution of CD68 and CD206 in HCC tissues and adjacent area

Liver histology results for CD68-positive and CD206-positive macrophages are depicted in [Fig. 1](#f1-or-38-02-0886){ref-type="fig"}. Among all specimens in our studies, CD68 expression was specific to macrophages and was shown in cell membrane and cytoplasm in brown color. Furthermore, the cells positively stained for CD206 often displayed typical macrophage morphology. CD68-positive and CD206-positive macrophages were infiltrated in both primary tumor tissues ([Fig. 1A and C](#f1-or-38-02-0886){ref-type="fig"}) and tumor adjacent tissues ([Fig. 1B and D](#f1-or-38-02-0886){ref-type="fig"}). However, the adjacent tissue was infiltrated with higher density of both CD68-positive and CD206-positive macrophages compared with intratumor compartments (P\<0.001 and P\<0.001, respectively). The average levels of CD68 and CD206 staining are shown in [Table IV](#tIV-or-38-02-0886){ref-type="table"}. Additionally, in tumor adjacent tissues, the density of infiltrated CD68-positive macrophages was much higher than that of CD206-positive macrophages (P\<0.001) and the same pattern can be seen in the intratumor area (P\<0.001).

Spearman\'s rank correlation coefficient analysis revealed a significant correlation in CD68 density between the intratumor tissues and the adjacent compartments (r=0.392; P\<0.001; [Fig. 2A](#f2-or-38-02-0886){ref-type="fig"}). Similar results were obtained in the CD206-positive macrophages (r=0.360; P\<0.001; [Fig. 2B](#f2-or-38-02-0886){ref-type="fig"}). This suggests a functional link between the intratumor macrophages and the adjacent macrophages. Notably, CD206 expression was positively correlated with CD68 expression in both intratumor tissues (r=0.237; P\<0.001; [Fig. 2C](#f2-or-38-02-0886){ref-type="fig"}) and adjacent tissues (r=0.261; P\<0.001; [Fig. 2D](#f2-or-38-02-0886){ref-type="fig"}) from HCC patients. It may imply some interaction between CD68 and CD206 cells.

### Correlation of CD68/CD206 density with clinical characteristics

The relationship between the expression of CD68 and CD206 in HCC and the clinicopathological features is listed in [Tables II](#tII-or-38-02-0886){ref-type="table"} and [III](#tIII-or-38-02-0886){ref-type="table"}. We noted that a higher CD68 density was found in the older patients intratumorally (P=0.027). Cases with portal hypertension (PHT) appeared to have lower intratumor CD68 expression compared with those without PHT (P=0.043), but the difference in adjacent tumor data did not reach a statistical significance (P=0.050). Patients whose AFP concentration was \>400 ng/ml might have much higher density of CD68 TAMs in both primary tumor tissues and tumor adjacent tissues (P=0.008 and P=0.026, respectively). Patients with high expression of CD68 in tumor adjacent tissue were prone to have a larger tumor size (P=0.012). As for CD206, its density in adjacent tissue was significantly higher in patients with cirrhosis (P=0.035) or poor TNM stages (P=0.013). The HCC cases with younger age or better Child-Pugh class had lower intratumor CD206 expression (P=0.001). Individuals with higher level of TBIL possessed decreased expression of CD206 (P=0.007) in tumor adjacent tissue. However, no statistical significance was observed in the expression of CD68 and CD206 with tumor differentiation, lymph node metastasis and alcohol intake.

### Diagnostic prediction of CD68/CD206 staining for HCC

AFP is a valuable serological biomarker. A level \>400 ng/ml was defined as cut-off value to evaluate sensitivity and specificity of CD68 and CD206. ROC curves showed that the optimal diagnostic cut-off for intratumor CD68 was 71/HPF \[area under curve (AUC) 0.614, (95% CI, 0.547--0.678), sensitivity 52.2% and specificity 70.7%; P=0.003\], and that for adjacent area was 87/HPF \[AUC 0.599, (0.534--0.661), 49.5 and 70.5%, P=0.008\] ([Fig. 3](#f3-or-38-02-0886){ref-type="fig"}). In contrast, the optimal cut-off value for intratumor CD206 was 25/HPF \[AUC 0.527, (0.465--0.588), sensitivity 56.2%, specificity 52.8%; P=0.463\] while the value for tumor-adjacent area was 83/HPF \[AUC 0.534, (0.469--0.599), 44.7, 69.2%; P=0.384\] ([Fig. 3](#f3-or-38-02-0886){ref-type="fig"}).

### Prognostic significance of CD206 and CD68 expression in HCC patients after operation

The prognostic value of CD68 and CD206 expression in postsurgical HCC patients was examined and data are shown in [Table V](#tV-or-38-02-0886){ref-type="table"} and [Fig. 4](#f4-or-38-02-0886){ref-type="fig"}. Within a median follow-up time of 44 months (1--54 months), 5-year OS and DFS rates for the 199 patients were 47 and 62%. The analyses showed that the median value for density of CD68 in intratumor was 61/HPF (CD68 density ≥61/HPF was defined as CD68^high^ group, CD68 density \<61/HPF was defined as CD68^low^ group) and that in adjacent area was 78/HPF (CD68 density ≥78/HPF was defined as CD68^high^ group, CD68 density \<78/HPF was defined as CD68^low^ group), respectively. Similarly, 29/HPF and 66/HPF were the medians of CD206 macrophage content for the two areas.

Survival analyses revealed that high density of CD206-positive macrophages in intratumor tissues was significantly associated with reduced OS (P=0.013; [Fig. 4E](#f4-or-38-02-0886){ref-type="fig"}) and DFS (P=0.003; [Fig. 4F](#f4-or-38-02-0886){ref-type="fig"}) in post-surgical HCC patients. On the contrary, we noted that increased CD68-positive macrophages were significantly correlated with better survival only in tumor adjacent area (P=0.020; [Fig. 4C](#f4-or-38-02-0886){ref-type="fig"}) and patients with low CD68 expression in adjacent area exhibited a worse DFS (P=0.018; [Fig. 4D](#f4-or-38-02-0886){ref-type="fig"}). However, no significant correlations of CD68-positive macrophages infiltrated in intratumor (P=0.906 and P=0.535, respectively; [Fig. 4A and B](#f4-or-38-02-0886){ref-type="fig"}) and CD206-positive macrophages in adjacent compartment with prognosis (P=0.330 and P=0.912, respectively; [Fig. 4G and H](#f4-or-38-02-0886){ref-type="fig"}).

Univariate analysis of prognostic factors revealed that CD68-positive macrophages in tumor adjacent tissue and CD206-positive macrophages in intratumor had significant prognostic effects on OS in post-surgical HCC patients (P=0.024 and P=0.014, respectively) ([Table V](#tV-or-38-02-0886){ref-type="table"}). In addition, both low CD68 density in tumor adjacent tissue (P=0.008) and high CD206 density in intratumor (P=0.016) were identified as independent predictors of poor prognosis for OS by multivariate survival analysis after adjustment of covariates ([Table V](#tV-or-38-02-0886){ref-type="table"}). Similar results were obtained for DFS. Increased CD68-positive macrophages in tumor adjacent tissue (P=0.016) and enhanced intratumor CD206-positive macrophages (P=0.003) played significant roles by univariate analysis. Multivariate survival analysis showed both CD68 density in tumor adjacent tissue (P=0.028) and CD206 density in intratumor tissue (P=0.005) could be as independent predictors for DFS ([Table V](#tV-or-38-02-0886){ref-type="table"}).

### Combination of adjacent area CD68 density with intratumoral CD206 density analysis

Patients were classified into four groups according to their intratumoral CD206 and adjacent tumoral CD68 densities ([Table V](#tV-or-38-02-0886){ref-type="table"}): group I (n=65), low CD206 and CD68 density; group II (n=39), high CD206 but low CD68 density; group III (n=46), low CD206 but high CD68 density; and group IV (n=49), high CD206 and CD68 density. Differences in both OS (P=0.040; [Fig. 5A](#f5-or-38-02-0886){ref-type="fig"}) and DFS (P=0.015; [Fig. 5B](#f5-or-38-02-0886){ref-type="fig"}) were significant among the four groups and group II had the worst survival.

### Combination of adjacent area CD68 density/intratumoral CD206 density with HBV

To assess whether the combined use of adjacent area CD68 density and HBV infective status was better than either of these biomarkers alone, four groups were assessed as follows ([Table V](#tV-or-38-02-0886){ref-type="table"} and [Fig. 6](#f6-or-38-02-0886){ref-type="fig"}): group I (n=69), high CD68 density and positive HBV; group II (n=27), high CD68 density but negative HBV; group III (n=80), low CD68 density but positive HBV; and group IV (n=23), low CD68 density and negative HBV. We found a significant difference in DFS (P=0.001; [Fig. 6B](#f6-or-38-02-0886){ref-type="fig"}), but not in OS (P=0.102; [Fig. 6A](#f6-or-38-02-0886){ref-type="fig"}) among the four groups. Group III with low CD68 density in adjacent tumor but positive HBV had the shortest recurrence time.

Similarly, another grouping approach is listed in [Table V](#tV-or-38-02-0886){ref-type="table"} and [Fig. 6C and D](#f6-or-38-02-0886){ref-type="fig"}. There were significant differences in either OS (P=0.043; [Fig. 6C](#f6-or-38-02-0886){ref-type="fig"}) or DFS (P\<0.001; [Fig. 6D](#f6-or-38-02-0886){ref-type="fig"}) among the four groups. Of note, group I had the poorest DFS. However, in univariate analysis, only difference in DFS (P\<0.001) is shown in [Table V](#tV-or-38-02-0886){ref-type="table"}. In brief, the combined predictive value in DFS was much greater than that of CD68 or CD206 alone.

Discussion
==========

Results from the present study demonstrate that changes to CD68-positive and CD206-positive macrophage subpopulations in tumor site and adjacent region in HCC are associated with OS and DFS. To the best of our knowledge, this is the first study that shows location-specific and subtype-specific macrophage expression and their prognostic values in HCC.

In the present study, the infiltrating CD68- and CD206-positive subpopulations were observed in cancer tissues and in adjacent tissues of HCC, with predominant presence in the adjacent tumor tissues. CD68-positive macrophages were much more abundant than CD206-positive macrophages both in the intratumor and adjacent areas. This is in accordance with the fact that the total number of CD68-positive macrophages is greater than that of CD206-positive M2 macrophages. According to the infiltrating macrophage count, there was a notable increase of CD68 expression in non-tumor tissues in line with the increased macrophage expression and inflammatory response in HCC demonstrated previously by others ([@b25-or-38-02-0886],[@b26-or-38-02-0886]). This result is in contrast to several investigations which showed overexpression of CD68 in tumor tissue ([@b27-or-38-02-0886]). This suggests the expression profile of CD68 in tumor and adjacent tumor-free region is specific to HCC. The increased number of CD68-positive macrophages in HCC adjacent samples in our analysis may be explained by heterogeneity of macrophages in response to different microenvironment signals. Thus, the subtype of CD68-positive macrophages in adjacent tissue is probably different from that in intratumor tissue and they may represent resident macrophages (CD68-positive Kupffer cells). Specifically, CD68-positive macrophages in adjacent tumor are more similar to macrophages in normal or inflamed tissues that possess spontaneous antitumor activity. Therefore, these cells would be beneficial in the prognosis of HCC ([@b28-or-38-02-0886]). These data suggest a possibility that as a front line defense to prevent tumor growth, the adjacent non-tumor liver tissue is endowed with abundant CD68-positive macrophages. Positive correlation of increased amount of adjacent CD68-positive macrophages with good HCC prognosis in the present study could be explained by the ability of macrophages that are not yet re-programmed by tumor cells to kill cancer cells. In other words, CD68-positive macrophages in adjacent tissue may have antitumor activity as they are uneducated into M2 phenotype by cancer, while in tumor the opposite happens. In tumor area, a genetic exchange between the primary tumor cells and the associated macrophages may lead to the expression of a more invasive phenotype of macrophages. On the other hand, immunohistochemistry with antibodies to CD206 also identified a higher CD206 density in adjacent tissue in HCC patients, which is similar to a study examining the higher proliferation of endothelial cells to IL-6/sIL-6R in HCC peritumor ([@b29-or-38-02-0886]). Generally, CD206 can identify mannose and fucose glycoconjugates and has been recognized as an important regulator in the phagocytosis of intracellular pathogens. Herein we speculate that this phagocytosis in tumor may consume a large number of CD206 so that the count of CD206 would be reduced dramatically in intratumor. However, the mechanism for overexpression of CD68 and higher density of CD206 in the adjacent liver tissue remains unclear. One possible mechanism is tumor cell-micro environmental crosstalk which is complex. Another possibility is that a line of defense surrounding tumor formed by tumor microenvironment may block the entrance of macrophages into the tumor. Furthermore, the tumor itself could be a possible stimulator either stimulating chronic inflammation or causing a host hepatocyte reaction ([@b26-or-38-02-0886]), resulting in elevated production of cytokines and more CD68/CD206 at the tumor-host margin. Moreover, the heterogeneity of macrophages in HCC raises a further possibility that there are different distributions and phenotypes of macrophages in different tumor parts and nearby areas. We propose that some genetic heterogeneity among different individuals may lead to the different baseline expression level of CD68/CD206. In this regard, previous evidence concerning the density of TAMs in HCC partly contrasts with our data. These discrepancies could be due to differences in the methodology, sample types, or patient characteristics. Two recent studies showed no association of CD68-positive macrophages in tumor region with clinicopathological characteristics in HCC but the tumor-adjacent region was not examined ([@b30-or-38-02-0886],[@b31-or-38-02-0886]). Additionally, associations between CD68-positive and CD206-positive macrophages in both tumor and adjacent tissues were also found in this study. A similar relationship between CD68-positive and CD163-positive macrophages in HCC was also previously reported ([@b21-or-38-02-0886]). This may suggest a possible interaction between macrophage subpopulations.

In the present study, low CD68 expression in tumor was associated with age and PHT, which could partly explain the protective role of CD68 in this study. On the contrary, patients with cirrhosis, poor TNM stages and Child-Pugh class tended to have high CD206 density, indicating the M2 role of CD206 in cancers. On the whole, a lower correlation between CD68-positive/CD206-positive macrophages and clinicopathological characteristics in HCC patients may imply some other genetic heterogeneity within different individuals. Our results also suggest that CD68 expression either in intratumor or in adjacent tumor may be a potential diagnostic measure of HCC. However, the effectiveness of this emerging marker requires further assessment.

Prognostic factors are of paramount interest in the risk assessment of cancer patients. This study demonstrated that the dense CD68 infiltration in the tumor adjacent tissues, but not in primary tumor tissues, was strongly associated with favorable survival of both OS and DFS for post-operative HCC patients in univariate and multivariate analyses. This is consistent with another report on esophageal squamous cell carcinoma ([@b32-or-38-02-0886]). However, CD68 has been frequently shown to correlate with an adverse prognosis in a variety of malignancies, such as oral squamous cell carcinoma and HCC ([@b21-or-38-02-0886]--[@b24-or-38-02-0886]). Recently, dual prognostic significance of CD68-positive TAMs has been reported in pancreatic ductal adenocarcinoma (PDAC) ([@b33-or-38-02-0886]). In this study, CD68-TAMs at the tumor-stroma interface may promote PDAC distant metastasis, while in patients who have received chemotherapy, TAMs play an opposite role. Additionally, some authors suggested that CD68-positive macrophages did not affect the outcome of patients with classical Hodgkin lymphoma ([@b34-or-38-02-0886]). A similar finding was reported recently by Shu *et al* ([@b30-or-38-02-0886]), however, we thought that the results could not comprehensively and accurately reveal the prognostic value of CD68 as they only analyzed HCC tissues for CD68-positive macrophages rather than adjacent tissues.

Macrophages in normal or inflamed tissues possess spontaneous antitumor activity, while TAMs seem to have distinct phenotypes with diverse functional programs within different local environment ([@b28-or-38-02-0886]). This might suggest that CD68-positive macrophages, exhibiting M1-like phenotype, serve as a protective phenotype and likely lessen HCC damage. Moreover, TAMs in HCC are heterogeneous and present different phenotypes as heterogeneity and plasticity are hallmarks of macrophages ([@b22-or-38-02-0886]). Possibly, there was different depletion or recruitment of heterogeneous populations of protumor and antitumor macrophages in the liver. Also, plasticity of macrophages allowed them to acquire either protumor or antitumor functions ([@b35-or-38-02-0886]). Thus, it was not surprising to find various functional phenotypes of macrophages in adjacent tissue versus intratumor tissue, as seen in the present study. Positive correlation of increased amount of adjacent CD68-positive macrophages with HCC prognosis in this study could be due to the macrophages that were not yet re-programmed into M2 phenotype by tumor cells and still possessed the ability of killing cancer cells.

In our HCC patient cohort, the increased CD206-positive M2 macrophages at primary tumor tissues were correlated with poor prognosis. The bulk of available information indicates that CD206-positive M2 macrophages appear to possess mostly tumor promoting property ([@b36-or-38-02-0886],[@b37-or-38-02-0886]). This is in line with a poor prognosis and hence the prognostic value of intratumor CD206 macrophages in HCC patients. Although intratumoral CD206-positive M2-macrophages were reported to promote tumor cell dissemination, the adjacent CD206-positive macrophages may play a different, even opposite role. Herein, intratumoral CD206-positive macrophages contributed to a propensity of metastases and poor prognosis for HCC. Our results strongly demonstrate that intratumoral CD206 is an independent factor of prognosis for postsurgical HCC patients. In contrast, another study reported an association of decreased CD206-positive macrophages with loss of interstitial cells of Cajal in patients with diabetic gastroparesis, indicating a cytoprotective role for CD206-positive macrophages ([@b38-or-38-02-0886]). These data may prompt a therapeutic strategy that targets intratumoral CD206 by reprogramming its protumor phenotype into an effective antitumor activity. Our findings with CD206-positive macrophages are consistent with two recent reports that CD206 in tumor region of HCC was linked to poor prognosis. However, by examining CD68/CD206-positive macrophages in both tumor tissues and adjacent tissues, our models have higher predicative power.

Furthermore, we found a much greater advantage in combining capability of intratumor CD206 with adjacent CD68 in prognostic prediction of HCC. There are greater numbers of younger patients with HBV-related HCC in Asian countries including China ([@b39-or-38-02-0886]), as shown in the present study ([Table I](#tI-or-38-02-0886){ref-type="table"}). The findings revealed a better prognostic value, especially in recurrence. According to the Cox regression model that included the levels of CD68/CD206-positive macrophage content, smoking, HBV, albumin, lymph node metastasis, primary lesion and TNM, it was concluded that primary lesion, adjacent CD68 and intratumor CD206 were independent prognostic factors for both OS and DFS.

In conclusion, this study clearly demonstrates higher densities of CD68 and CD206 in the adjacent liver tissue than those in tumor tissue. The dense CD206 macrophage infiltration at the tumor is an independent predictor of poor survival in postsurgical HCC patients. High density of CD68 macrophage infiltration in adjacent tissue is capable of predicting improved survival. The findings from this study suggest the complexity of macrophages within and surrounding tumor microenvironment, a novel role for CD68/CD206-positive macrophages and a basis for targeting these cells as new therapeutic strategies for HCC patients.
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![CD68-positive and CD206-positive macrophages in HCC tissues and adjacent tissues. Immunoreactivity to anti-CD68 (A and B) and anti-CD206 (C and D) in tumor tissues (A and C) and adjacent tissues (B and D) of HCC.](OR-38-02-0886-g00){#f1-or-38-02-0886}

###### 

Correlation between infiltrated CD68-positive and CD206-positive macrophages in different areas of HCC. (A) CD68 expression between intratumor tissues and adjacent tissues (r=0.392; P\<0.001). (B) CD206 expression in intratumor tissues and adjacent tissues (r=0.360; P\<0.001). (C) Positive correlation between CD206 and CD68 in intratumor tissues (r=0.237; P\<0.001). (D) Positive correlation between CD206 and CD68 in adjacent tissues (r=0.261; P\<0.001).

![](OR-38-02-0886-g01)

![](OR-38-02-0886-g02)

![](OR-38-02-0886-g03)

![](OR-38-02-0886-g04)

![The optimal diagnostic cut-off for intratumor CD68 was 71/hpf and 87/hpf for adjacent tumoral CD68 in the diagnosis of HCC.](OR-38-02-0886-g05){#f3-or-38-02-0886}

###### 

OS and DFS for infiltrated CD206-positive and CD68-positive macrophages in different tumor areas of post-surgical HCC patients. In HCC patients after operation, the low CD68 expression in adjacent tumor and high density of CD206-positive macrophages in intratumor tissues were significantly associated with reduced OS and DFS (C-F). However, no significant association of CD68-positive macrophages infiltrated in intratumor and CD206-positive macrophages in adjacent compartment with prognosis was found (A, B, G and H).
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OS and DFS for combination of adjacent tumoral CD68 density with intratumoral CD206 density. Combined analysis of adjacent tumoral CD68 with intratumoral CD206, differences in both OS (A) and DFS (B) were significant.
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###### 

OS and DFS for combination of adjacent tumoral CD68 density/intratumoral CD206 density with HBV. Combination of either adjacent CD68 or intratumoral CD206 with HBV, was significantly different in DFS (B and D). There was significant difference in OS for the combination of intratumoral CD206 with HBV (C), but not for combination of either adjacent CD68 or HBV (A).
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###### 

Clinicopathological characteristics of HCC patients.

  Clinical variables                     n (%)
  -------------------------------------- -------------
  Sex                                    
    Male                                 229 (85.4)
    Female                                 39 (14.6)
  Age (years)                            
    \<54                                 133 (49.6)
    ≥54                                  135 (50.4)
  Alcohol intake                         
    Yes                                    95 (35.4)
    No                                   173 (64.6)
  HBV                                    
    Positive                             209 (78.0)
    Negative                               59 (22.0)
  Liver cirrhosis                        
    Present                              112 (41.8)
    Absent                               156 (58.2)
  PHT                                    
    Present                              19 (7.1)
    Absent                               249 (92.9)
  TBIL (µmol/l)                          
    \<34                                 257 (95.9)
    ≥34                                    8 (3.0)
    NG                                     3 (1.1)
  AFP (ng/ml)                            
    \<400                                161 (60.1)
    ≥400                                 107 (39.9)
  Child-Pugh class                       
    A                                    238 (88.8)
    B                                    26 (9.7)
    C                                      4 (1.5)
  Tumor size (cm)                        
    \<5                                  130 (48.5)
    ≥5                                   138 (51.5)
  Lymph node metastasis                  
    Present                                4 (1.5)
    Absent                               253 (94.4)
    NG                                   11 (4.1)
  TNM stage                              
    I + II                               203 (75.8)
    III + IV                             65 (23.2)
  Degree of histologic differentiation   
    High                                   28 (10.5)
    Moderate                             111 (41.4)
    Low                                  104 (38.8)
    NG                                   25 (9.3)

HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; NG, not get.

###### 

Correlation of CD68-positive expression with clinicopathological characteristics of HCC patients.

                          Intratumor CD68   Adjacent CD68                                 
  ----------------------- ----------------- --------------- ------- ------- ------------- -------
  Sex                                                       0.125                         0.142
    Male                  190               65.42±32.11             206     77.62±23.04   
    Female                  35              74.71±36.18               37    83.62±21.47   
  Age (years)                                               0.027                         0.893
    \<54                  106               61.86±27.53             117     78.45±22.66   
    ≥54                   118               71.42±36.66             125     78.85±23.10   
  Alcohol intake                                            0.901                         0.258
    Yes                     79              66.49±30.13               83    80.84±24.52   
    No                    146               67.07±34.36             160     77.34±21.95   
  HBV                                                       0.954                         0.030
    Positive              171               66.80±32.99             188     76.81±21.90   
    Negative                54              67.09±32.77               55    84.42±25.26   
  Liver cirrhosis                                           0.633                         0.946
    Present                 91              65.59±34.68             103     78.65±22.68   
    Absent                134               67.73±31.68             140     78.45±23.09   
  PHT                                                       0.043                         0.050
    Present                 19              52.26±21.37               18    68.39±18.48   
    Absent                206               68.21±33.45             225     79.35±23.03   
  TBIL                                                      0.258                         0.202
    \<34                  214               67.36±32.30             232     78.81±23.01   
    ≥34                       8             53.88±50.26                 8   68.25±20.77   
  AFP (ng/ml)                                               0.008                         0.026
    \<400                 133               62.03±30.84             146     75.88±23.18   
    ≥400                    92              73.86±34.59               97    82.54±21.91   
  Child-Pugh class                                          0.470                         0.209
    A                     197               67.60±32.73             215     79.20±22.82   
    B                       24              63.83±36.34               24    71.21±22.82   
    C                         4             48.75±4.43                  4   86.50±22.25   
  Tumor size (cm)                                           0.072                         0.012
    \<5                   103               62.74±33.33             107     75.57±21.46   
    ≥5                    115               70.66±31.21             127     83.00±23.34   
  Lymph node metastasis                                     0.654                         0.523
    Present                   8             72.00±26.67                 8   83.63±12.31   
    Absent                217               66.68±33.11             235     78.36±23.14   
  TNM stage                                                 0.143                         0.491
    I + II                168               64.99±33.84             185     77.97±23.37   
    III + IV                57              72.39±29.40               58    80.34±21.29   
  Tumor differentiation                                     0.767                         0.283
    Well                    26              62.88±38.15               27    84.74±18.60   
    Moderate                88              68.13±29.20               99    77.00±21.79   
    Poor                    91              67.21±33.43               94    79.01±24.02   

SD, standard deviation; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis.

###### 

Correlation of CD206-positive expression with clinicopathological characteristics of HCC patients.

                          Intratumor CD206   Adjacent CD206                                 
  ----------------------- ------------------ ---------------- ------- ------- ------------- -------
  Sex                                                         0.013                         0.297
    Male                  227                30.50±14.47              202     77.62±23.04   
    Female                  39               37.03±17.75                35    83.62±21.47   
  Age (years)                                                 0.828                         0.185
    \<54                  131                31.73±14.42              118     65.83±16.35   
    ≥54                   134                31.32±15.84              118     63.10±15.18   
  Alcohol intake                                              0.574                         0.813
    Yes                     93               32.14±13.76                84    64.73±15.67   
    No                    173                31.09±15.85              153     64.22±15.93   
  HBV                                                         0.375                         0.365
    Positive              208                31.02±14.84              183     63.89±15.88   
    Negative                58               33.02±16.21                54    66.11±15.56   
  Liver cirrhosis                                             0.177                         0.035
    Present               111                29.97±13.35                98    61.82±16.22   
    Absent                155                32.52±16.25              139     66.22±15.30   
  PHT                                                         0.971                         0.240
    Present                 19               31.58±10.89                13    59.38±18.38   
    Absent                247                31.45±15.43              224     64.69±15.64   
  TBIL                                                        0.349                         0.007
    \<34                  255                31.15±15.19              228     64.74±15.61   
    ≥34                       8              36.25±13.51                  6   47.00±16.86   
  AFP (ng/ml)                                                 0.486                         0.338
    \<400                 161                30.93±14.95              143     65.20±15.05   
    ≥400                  105                32.26±15.45                94    63.18±16.89   
  Child-Pugh class                                            0.001                         0.240
    A                     236                31.01±14.63              213     64.96±15.63   
    B                       26               31.27±13.22                21    58.86±15.86   
    C                         4              59.00±31.52                  3   63.33±26.31   
  Tumor size (cm)                                             0.886                         0.385
    \<5                   129                31.32±15.14              113     63.46±14.92   
    ≥5                    137                31.58±15.18              124     65.25±16.59   
  Lymph node metastasis                                       0.734                         0.859
    Present                   8              33.25±27.73                  8   65.38±18.90   
    Absent                258                31.40±14.67              229     64.36±15.73   
  TNM stage                                                   0.357                         0.013
    I + II                201                30.96±14.97              181     62.99±15.88   
    III + IV                65               33.00±15.65                56    68.95±14.78   
  Tumor differentiation                                       0.445                         0.644
    Well                    28               28.07±10.65                24    66.08±13.39   
    Moderate              111                31.72±13.47                99    65.07±15.34   
    Poor                  102                32.00±17.07                92    63.29±17.22   

SD, standard deviation; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis.

###### 

Difference in the density of CD68-positive and CD206-positive macrophages in tumor and adjacent tissue (mean ± SD).

                 Density                 
  -------------- --------- ------------- ---------
  CD68                                   \<0.001
    Intratumor   216       66.59±32.89   
    Adjacent     216       79.41±23.42   
  CD206                                  \<0.001
    Intratumor   236       31.55±15.03   
    Adjacent     236       64.36±15.83   
  Intratumor                             \<0.001
    CD68         223       66.61±32.89   
    CD206        223       30.42±15.13   
  Adjacent                               \<0.001
    CD68         220       79.89±22.64   
    CD206        220       63.95±15.85   

###### 

Univariate and multivariate analysis of different parameters with survival and recurrence in HCC patients.

                                       OS        DFS                                                                 
  ------------------------------------ --------- ------- --------------- --------- --------- ------- --------------- -------
  Alcohol intake                       0.257                             NA        0.212                             NA
    Yes vs. no                                                                                                       
  Smoking                              0.012     1.717   1.069--2.759    0.025     0.866                             NA
    Yes vs. no                                                                                                       
  HBV                                  0.212                             NA        0.003     3.898   1.400--10.854   0.009
    Positive vs. negative                                                                                            
  Liver cirrhosis                      0.448                             NA        0.961                             NA
    Present vs. absent                                                                                               
  PHT                                  0.436                             NA        0.334                             NA
    Present vs. absent                                                                                               
  TBIL                                 0.867                             NA        0.699                             NA
    \<34 vs. ≥34                                                                                                     
  Albumin                              0.026     0.360   0.205--0.632    \<0.001   0.280                             NA
    \<35 vs. ≥35                                                                                                     
  AFP                                  0.438                             NA        0.206                             NA
    \<400 vs. ≥400                                                                                                   
  Child-Pugh class                     0.740                             NA        0.865                             NA
    A vs. B vs. C                                                                                                    
  Tumor size                           0.311                             NA        0.936                             NA
    \<5 vs. ≥5                                                                                                       
  Lymph node metastasis                \<0.001   8.238   3.126--21.710   \<0.001   0.460                             NA
    Present vs. absent                                                                                               
  Primary lesion                       \<0.001   1.531   1.295--1.811    \<0.001   0.054     1.214   1.001--1.473    0.049
  TNM stage:                           \<0.001   2.052   1.637--2.571    \<0.001   0.326                             NA
    I + I vs. III + IV                                                                                               
  Tumor differentiation                0.421                             NA        0.206                             NA
    Well vs. moderate vs. poor                                                                                       
  Intratumor features                                                    NA                                          NA
    Low vs. high                                                                                                     
  CD68 density                         0.907                                       0.538                             
  CD206 density                        0.014     1.792   1.116--2.879    0.016     0.003     2.222   1.280--3.856    0.005
  Adjacent tumor features                                                                                            
    Low vs. high                                                                                                     
  CD68 density                         0.024     0.510   0.311--0.837    0.008     0.016     0.529   0.299--0.935    0.028
  CD206 density                        0.334                             NA        0.912                             NA
  Combine adjacent tumoral             0.040                             NA        0.015                             NA
  CD68 and intratumoral CD206                                                                                        
  Combine adjacent tumoral             0.014                             NA        0.326                             NA
  CD68 and HBV                                                                                                       
  Combine intratumoral CD206 and HBV   0.070                             NA        \<0.001                           NA

OS, overall survival; DFS, disease-free survival; NA, not adopted; HBV, hepatitis B virus; PHT, portal hypertension; TBIL, total bilirubin; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval.
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